Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28819817 | 0.86 | SLC6A4 (0.40) | GCKALDH1A1HPGD | |
| SCHEMBL2645380 | 0.85 | SLC6A3 (0.40) | ESR1ESR2GCKL3MBTL1SLC6A3 | |
| SCHEMBL2646161 | 0.85 | AKR1C3 (0.40) | GCKALDH1A1HPGD | |
| SCHEMBL1107404 | 0.85 | AKR1C3 (0.40) | GCKALDH1A1HPGD | |
| SCHEMBL12742235 | 0.85 | GCK (0.38) | ESR1ESR2GCKALDH1A1HPGD | |
| SCHEMBL2645826 | 0.83 | L3MBTL1 (0.56) | ESR1ESR2RAB9AL3MBTL1SLC6A3 | |
| SCHEMBL2645875 | 0.83 | POLB (0.46) | ESR1ESR2RAB9AGCKL3MBTL1 | |
| SCHEMBL2648101 | 0.83 | SLC6A3 (0.52) | ESR1ESR2GCKL3MBTL1SLC6A3 | |
| SCHEMBL1418963 | 0.83 | SLC6A3 (0.50) | SLC6A3ALDH1A1 | |
| SCHEMBL2646358 | 0.82 | MEN1 (0.45) | ESR1ESR2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6528543-B1 | Glucokinase activating for treating type II diabetes; acylurea compound, phenylacetyl-substituted; 1-(2-(3-chloro-phenyl)-3cyclopentyl-propionyl)-3-methyl-urea | HOFFMAN-LA ROCHE INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |